-
Silexion Therapeutics completes 1-for-10 reverse share split; warrants adjusted
1-for-10 reverse share split effective after close May 28; shares trade on split-adjusted basis May 29 under ticker SLXN.
-
Silexion Therapeutics announces 1-for-10 reverse share split to maintain Nasdaq listing
Reverse share split at 1:10 ratio; effective after market close May 28, 2026; split-adjusted trading begins May 29, 2026.
-
Silexion Therapeutics Q1 net loss $2.7M; cash $2.4M; Phase 2/3 trial on track for Q2 2026
Net loss of $2.7M for Q1 2026 vs $1.7M in Q1 2025; R&D expenses rose 133% to $1.4M driven by trial preparation.
-
Silexion Therapeutics enters inducement agreement for exercise of ~2M warrants at $0.50, raising ~$1M
Holders of 1,995,092 existing warrants (Series A/B at $4.00, Prior Inducement at $11.32) agree to exercise at reduced price of $0.50 per share.
-
Silexion reports positive preclinical SIL204 data showing increased MHC-I in KRAS-mutated pancreatic cancer
SIL204 significantly increased MHC-I (HLA-ABC) surface expression in human KRAS G12R pancreatic cancer cells at 60 nM (p<0.05).
-
Silexion begins GMP manufacturing of SIL204 with Catalent; Phase 2/3 trial approved at Israeli site
Initiated GMP clinical batch manufacturing of SIL204 with Catalent at its Limoges, France center of excellence.
-
Silexion shareholders approve 50M share increase, expanded equity plan, and 1-for-10 reverse split
Authorized shares increased from 9M to 59M via Memorandum Amendment effective May 5, 2026.
-
Silexion submits Phase 2/3 trial application to Germany's BfArM for SIL204 in KRAS-driven pancreatic cancer
Silexion submitted CTA to Germany’s BfArM for Phase 2/3 trial of SIL204 in KRAS-driven locally advanced pancreatic cancer.
-
Silexion Therapeutics removes director Ilan Levin effective March 25, 2026
Ilan Levin removed from Board on March 25, 2026 by unanimous vote of other directors.
-
Silexion gets Israeli MoH approval for Phase 2/3 trial of SIL204 in pancreatic cancer
SIL204 is a next-generation RNAi therapy targeting multiple KRAS mutations in pancreatic cancer.
-
Silexion Therapeutics shareholders vote down share capital increase and equity plan expansion
At reconvened EGM on March 23, 2026, quorum met with 1,216,369 shares (36.6% of outstanding).
-
Silexion Therapeutics files 8-K disclosing corporate presentation for non-deal roadshow
Filed Form 8-K on February 3, 2026, with Items 7.01 and 9.01.
-
Silexion CEO letter details 2025 progress; Phase 2/3 trial in LAPC set for H1 2026
SIL204 showed >90% inhibition in human cancer cell lines across 8 KRAS mutations and 5 tumor types.
-
Silexion submits Phase 2/3 trial application for SIL204 in locally advanced pancreatic cancer
Submitted Phase 2/3 clinical trial application in Israel for SIL204, a siRNA therapy for locally advanced pancreatic cancer (LAPC).
-
Silexion receives positive BfArM feedback on Phase 2/3 trial design for SIL204 in pancreatic cancer
BfArM written Scientific Advice supports proposed Phase 2/3 study design, dosing, patient population, and CMC.
-
Silexion completes toxicology studies for SIL204; Phase 2/3 trial on track for Q2 2026
Two-species toxicology studies for SIL204 confirm no systemic organ toxicity, clearing path to regulatory filings.
-
Silexion Q3 net loss narrows to $3.3M; cash $9.2M; Phase 2/3 trial on track for H1 2026
Net loss $3.3M ($2.88/share) vs $11.9M ($274.25) a year ago, aided by lower share-based compensation.
-
Silexion reports SIL204 shows up to 99.7% inhibition across 11 human cell lines, first gastric cancer data
SIL204 achieved 83.5% to 99.7% inhibition at nanomolar concentrations (IC50 23.4–85.3 nM) in 11 lines from 5 cancer types.
-
Silexion Therapeutics enters ATM equity facility for up to $13.17M via H.C. Wainwright
At-the-market offering agreement with H.C. Wainwright to sell up to $13.17M of ordinary shares.
-
Silexion Therapeutics regains Nasdaq compliance; subject to one-year monitor
Received Nasdaq compliance letter on Sep 23, 2025 for equity (≥$2.5M) and minimum bid price ($1.00) requirements.
-
Silexion regains Nasdaq compliance with $9.4M equity after capital raise
Issued 450,000 shares to sponsor upon converting $1.8M of convertible note at $4.00/share; remaining $1.6M outstanding.
-
Silexion Therapeutics prices $6.0M public offering of shares and warrants
Raised $6.0M gross ($5.2M net) from sale of 1.5M share equivalents and warrants at $4.00/unit.
-
Silexion reports preclinical data showing SIL204 reaches metastatic sites in pancreatic cancer model
Subcutaneous SIL204 (5 mg/mouse) distributed to liver, peritoneum, lung in Panc-1 KRAS G12D metastatic model.
-
Silexion selects CRO AMS for SIL204 Phase 2/3 trials; H1 2026 start expected
CRO AMS has over 28 years of drug development experience and Phase 3 oncology trial expertise.
-
Silexion posts updated corporate presentation for H.C. Wainwright conference
Updated corporate presentation posted to company website on September 2, 2025.
-
Silexion Therapeutics 2024 net loss $16.5M, auditor flags going concern doubt
Net loss of $16.5M in 2024 vs $5.1M in 2023; operating expenses $12.6M.
-
Silexion Therapeutics shareholders approve 6x increase in authorized shares to 9M
Authorized capital raised from US$20,000 (1,481,482 shares) to US$121,500 (9,000,000 shares).
-
Silexion Q2 net loss $2.5M, cash $3.5M; SIL204 shows up to 97% inhibition across KRAS cancers
Net loss $2.5M for Q2 2025 vs $1.5M in Q2 2024; operating expenses up 64.3% to $2.3M.
-
Silexion exercises 152K warrants at $11.57 for ~$1.8M gross; issues new warrants
Exercises 152,106 existing warrants at $11.57/share; gross proceeds ~$1.8M before fees.
-
Silexion reports new preclinical data: up to 97% cancer cell inhibition, first evidence against KRAS Q61H mutation
SIL204 achieved up to 97% inhibition in pancreatic cancer cells with KRAS Q61H mutation (previously untested).
-
Silexion Therapeutics effects 1-for-15 reverse stock split, adjusts warrant terms
Reverse split effective after close July 28; trading on split-adjusted basis July 29 under same ticker SLXN.
-
Silexion receives Nasdaq bid price deficiency notice; reverse split set for July 29
On July 18, 2025, Nasdaq notified Silexion that its ordinary shares' closing bid price was below $1.00 for 30 consecutive days.
-
Silexion Therapeutics announces 1-for-15 reverse share split to maintain Nasdaq listing
Reverse split effective after market close July 28; split-adjusted trading starts July 29 under ticker SLXN.
-
Silexion shareholders approve 1-for-15 reverse split and board election
Reverse share split at 1-for-15 ratio approved with 59.6% of votes in favor.
-
SIL204 shows dose-dependent inhibition in KRAS G12D lung cancer cells in preclinical study
Preclinical study demonstrates significant dose-dependent inhibition of human lung cancer cells with KRAS G12D mutation.
-
Silexion amends 8-K, delays Nasdaq transfer; reverse split expected in August to cure bid price deficiency
Nasdaq transfer to Capital Market not on July 8 as originally reported; now expected as soon as practicable.
-
Silexion Therapeutics wins Nasdaq hearing to stay listed; transfer to Capital Market with equity conditions
Nasdaq panel granted continued listing subject to achieving $2.5M shareholders' equity by Sept 19, 2025.
-
Silexion Therapeutics appeals Nasdaq delisting; hearing set for June 26, 2025
Received Nasdaq delisting notice on May 22 for MVLS <$50M and MVPHS <$15M deficiencies.
-
Silexion SIL204 shows ~90% inhibition in colorectal cells; expands to lung & pancreatic
SIL204 inhibited GP2D colorectal cancer cells with ~90% inhibition rate in preclinical study.
-
Silexion Therapeutics receives Nasdaq delisting notice; plans appeal
Received delisting notice on May 22, 2025 for MVLS <$50M and MVPHS <$15M non-compliance.
-
Silexion Therapeutics completes preclinical studies of SIL204 in KRAS-driven colorectal, lung, and pancreatic cancers
SIL204 evaluated in GP2D (colorectal), A427 (lung), and Panc-1 (pancreatic) KRAS-mutant cell lines.
-
Silexion Therapeutics Q1 2025 net loss $1.7M; cash $6.2M; SIL204 shows ~70-80% tumor reduction
Net loss $1.7M in Q1 2025 vs $1.4M in Q1 2024; total operating expenses $1.7M (R&D $0.6M, G&A $1.1M).
-
Silexion partners with Catalent for siRNA formulation and manufacturing of SIL204
Collaboration with Catalent for SIL204 formulation development and clinical manufacturing at Limoges, France facility.
-
Silexion expands SIL204 development with dual-route plan; preclinical data support; H1 2026 human trials targeted
Expanded development plan for SIL204 combines intratumoral and systemic administration for KRAS-driven pancreatic cancer.
-
Silexion Therapeutics reports FY2024 results: net loss $16.5M, cash $1.2M, and progress on SIL204
Net loss for 2024 was $16.5 million, compared to $5.1 million in 2023.
-
Silexion retires $880K convertible note with $400K cash and 277,777 shares
Agreed to retire $880,202.20 outstanding convertible note issued to EarlyBirdCapital; pays $400K cash plus $15K legal fees.
-
Silexion Therapeutics reports positive initial data from SIL204 in orthotopic pancreatic cancer models
SIL204 reduced primary tumor bioluminescence by ~70% in AsPC-1 (KRAS G12D) and ~80% in BxPC-3 (wild-type) models by day 28.
-
Silexion Therapeutics secures ~$3.3M via warrant exercise inducement, issues new warrants
Holders exercise 2,221,523 existing warrants at $1.35 per share; new warrants issued for same number at $1.50.
-
Silexion reports preclinical data: SIL-204 systemic admin reduces pancreatic tumor growth ~50%
Extended-release SIL-204 reduced tumor growth ~50% after 30 days; ~50% of tumors showed complete necrosis in G12D xenografts.
-
Silexion Therapeutics prices ~$5M public offering of shares and warrants at $1.35/unit
Gross proceeds expected ~$5M; net proceeds ~$4.26M after placement agent fees and expenses.